2026 related articles for article (PubMed ID: 33556464)
1. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
[TBL] [Abstract][Full Text] [Related]
2. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
3. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
4. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia.
Mikulska M; Nicolini LA; Signori A; Di Biagio A; Sepulcri C; Russo C; Dettori S; Berruti M; Sormani MP; Giacobbe DR; Vena A; De Maria A; Dentone C; Taramasso L; Mirabella M; Magnasco L; Mora S; Delfino E; Toscanini F; Balletto E; Alessandrini AI; Baldi F; Briano F; Camera M; Dodi F; Ferrazin A; Labate L; Mazzarello G; Pincino R; Portunato F; Tutino S; Barisione E; Bruzzone B; Orsi A; Schenone E; Rosseti N; Sasso E; Da Rin G; Pelosi P; Beltramini S; Giacomini M; Icardi G; Gratarola A; Bassetti M
PLoS One; 2020; 15(8):e0237831. PubMed ID: 32817707
[TBL] [Abstract][Full Text] [Related]
6. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
7. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
[TBL] [Abstract][Full Text] [Related]
10. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
CORIMUNO-19 Collaborative group
Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
[TBL] [Abstract][Full Text] [Related]
11. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19: A Randomized Phase 2/3 Clinical Trial.
Fanlo P; Gracia-Tello BDC; Fonseca Aizpuru E; Álvarez-Troncoso J; Gonzalez A; Prieto-González S; Freire M; Argibay AB; Pallarés L; Todolí JA; Pérez M; Buján-Rivas S; Ibáñez B;
JAMA Netw Open; 2023 Apr; 6(4):e237243. PubMed ID: 37027155
[TBL] [Abstract][Full Text] [Related]
13. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
14. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
15. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
[TBL] [Abstract][Full Text] [Related]
16. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
17. High dose subcutaneous Anakinra to treat acute respiratory distress syndrome secondary to cytokine storm syndrome among severely ill COVID-19 patients.
Iglesias-Julián E; López-Veloso M; de-la-Torre-Ferrera N; Barraza-Vengoechea JC; Delgado-López PD; Colazo-Burlato M; Ubeira-Iglesias M; Montero-Baladía M; Lorenzo-Martín A; Minguito-de-la-Iglesia J; García-Muñoz JP; Sanllorente-Sebastián R; Vicente-González B; Alemán-Alemán A; Buzón-Martín L
J Autoimmun; 2020 Dec; 115():102537. PubMed ID: 32843231
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19.
Cauchois R; Koubi M; Delarbre D; Manet C; Carvelli J; Blasco VB; Jean R; Fouche L; Bornet C; Pauly V; Mazodier K; Pestre V; Jarrot PA; Dinarello CA; Kaplanski G
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):18951-18953. PubMed ID: 32699149
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
